{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T17:01:43Z","timestamp":1790096503841,"version":"4.0.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2006,1,28]],"date-time":"2006-01-28T00:00:00Z","timestamp":1138406400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2006,1,28]],"date-time":"2006-01-28T00:00:00Z","timestamp":1138406400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s10637-005-4345-3","type":"journal-article","created":{"date-parts":[[2006,1,28]],"date-time":"2006-01-28T10:14:51Z","timestamp":1138443291000},"page":"335-341","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Phase II trial of R115777 (NSC #70818) in patients with advanced colorectal cancer: A Southwest Oncology Group study"],"prefix":"10.1007","volume":"24","author":[{"given":"Robert P.","family":"Whitehead","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheryl","family":"McCoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John S.","family":"Macdonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul E.","family":"Rivkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus A.","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaker R.","family":"Dakhil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L.","family":"Abbruzzese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2006,1,28]]},"reference":[{"key":"4345_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.3322\/canjclin.54.1.8","volume":"54","author":"A Jemal","year":"2004","unstructured":"Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ, Thun MJ: Cancer Statistics, 2004. CA Cancer J Clin 54:8\u20139, 2004","journal-title":"CA Cancer Journal for Clinicians"},{"key":"4345_CR2","unstructured":"Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Mariotto A, Fay MP, Feuer EJ, Edwards BK (eds): SEER Cancer Statistics Review, 1975\u20132000, National Cancer Institute. Bethesda, MD,http:\/\/seer.cancer.gov\/csr\/1975_2000, 2003"},{"key":"4345_CR3","first-page":"1216","volume-title":"Principles and Practice of Oncology","author":"JM Skibber","year":"2001","unstructured":"Skibber JM, Minsky BD, Hoff PM: Cancer of the Colon. And Cancer of the Rectum Sections 7 and 8 in Chapter 33, Cancers of the Gastrointestinal Tract. In: DeVita Jr VT, Hellman S, Rosenberg SA (eds.), Cancer Principles and Practice of Oncology, 6th edition. Philadelphia, PA: Lippincott Williams and Wilkins, 2001, pp. 1216\u2013319","edition":"6th edition"},{"issue":"13","key":"4345_CR4","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1056\/NEJM200009283431302","volume":"343","author":"LB Saltz","year":"2000","unstructured":"Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, Elfring GL, Miller LL: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 343(13):905\u201314, 2000","journal-title":"N Engl J Med."},{"issue":"16","key":"4345_CR5","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A de Gramont","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, Papamichael D, LeBail N, Louvet C, Hendler D, de Braud F, Wilson C, Morvan F, Bonetti A: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18(16):2938\u2013947, 2000","journal-title":"J Clin Oncol."},{"key":"4345_CR6","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1200\/JCO.2004.05.113","volume":"22","author":"C Tournigand","year":"2004","unstructured":"Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Onco 22:229\u201337, 2004","journal-title":"Journal of Clinical Oncology"},{"issue":"4676","key":"4345_CR7","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1126\/science.6436980","volume":"226","author":"JB Hurley","year":"1984","unstructured":"Hurley JB, Simon MI, Teplow DB, Robishaw JD, Gilman AG: Homologies between signal transcription G proteins and ras gene products. Science 226(4676):860\u201362, 1984","journal-title":"Science"},{"issue":"2-3","key":"4345_CR8","first-page":"215","volume":"1072","author":"H Haubruck","year":"1991","unstructured":"Haubruck H, McCormick F: Ras p21: Effects and regulation. Biochim Biol Acta 1072(2\u20133): 215\u201329, 1991","journal-title":"Biochim Biol Acta"},{"key":"4345_CR9","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/327293a0","volume":"327","author":"JL Bos","year":"1987","unstructured":"Bos JL, Fearon ER, Hamilton SR, Verlan-de Vries M, van Boom JH, van Eb AJ, Vogelstein B: Prevalence of ras gene mutation in colorectal cancers. Nature 327:293\u201397, 1987","journal-title":"Nature"},{"key":"4345_CR10","first-page":"123","volume":"39","author":"ER Feron","year":"1994","unstructured":"Feron ER: Molecular genetic studies of the adenoma-carcinoma sequence. Adv Med 39:123\u201347, 1994","journal-title":"Adv. Med."},{"key":"4345_CR11","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1136\/gut.44.6.826","volume":"44","author":"A Rashid","year":"1999","unstructured":"Rashid A, Cahurak M, Goodman SN, Hamilton SR: Genetic epidemiologically mutated K-ras proto-oncogene, altered suppressor genes and microsatellite instability in colorectal adenomas. Gut 44:826\u201333, 1999","journal-title":"Gut"},{"key":"4345_CR12","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/0959-8049(92)90468-H","volume":"28A","author":"L Losi","year":"1992","unstructured":"Losi L, Benhattar J, Costa J: Stability of K-ras mutations throughout the natural history of human colorectal cancer. Eur J Cancer 28A:1115\u2013120, 1992","journal-title":"European Journal of Cancer"},{"key":"4345_CR13","first-page":"1149","volume":"58","author":"G Quan","year":"1998","unstructured":"Ahnen DJ, Feigl P, Quan G, Fenoglio-Preiser C, Lovato LC, Bunn PA Jr, Stemmerman G, Wells JD, Macdonald JS, Meyskens FL Jr: Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: A Southwest Oncology Group Study. Cancer Res 58:1149\u2013158, 1998","journal-title":"Cancer Research"},{"key":"4345_CR14","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S0140-6736(86)90422-8","volume":"2","author":"LP Fielding","year":"1986","unstructured":"Fielding LP, Phillips RKS, Fry JS, Hittinger R: Prediction of outcome after curative resection for large bowel cancer. Lancet 2:904, 1986","journal-title":"Lancet"},{"key":"4345_CR15","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrc969","volume":"3","author":"J Downward","year":"2003","unstructured":"Downward J: Targeting ras signaling pathways in cancer therapy. Nat Rev Cancer 3:11\u20132, 2003","journal-title":"Nature Reviews Cancer"},{"key":"4345_CR16","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1126\/science.8316833","volume":"260","author":"NE Kohl","year":"1993","unstructured":"Kohl NE, Mosser SD, deSolms SJ, Giuliani EA, Pompliano DL, Graham SL, Smith RL, Scolnick EM, Oliff A, Gibbs JB: Selective inhibition of ras-dependent transformation by a farnesyltransferase inhibitor. Science 260:1934\u2013937, 1993","journal-title":"Science"},{"key":"4345_CR17","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1126\/science.8316834","volume":"260","author":"GL James","year":"1993","unstructured":"James GL, Goldstein JL, Brown MS, Rawson TE, Somers TC, McDowell RS, Crowley CW, Lucas BK, Levinson AD, Marsters Jr JC: Benzodiazepine peptidomimetics: Potent inhibitors of ras farnesylation in animal cells. Science 260:1937\u2013942, 1993","journal-title":"Science"},{"key":"4345_CR18","first-page":"5310","volume":"55","author":"N Nakeshi","year":"1995","unstructured":"Nakeshi N, Yoshimatsu K, Rowell C, Lewis MD, Garcia AM: Inhibition of human tumor xenograft growth by treatment with the farnesyltransferase inhibitor B956. Cancer Res 55:5310\u2013314, 1995","journal-title":"Cancer Research"},{"key":"4345_CR19","first-page":"5302","volume":"55","author":"L Sepp-Lorenzino","year":"1995","unstructured":"Sepp-Lorenzino L, Ma Z, Rands E, Kohl NE, Gibbs JB, Oliff A, Rosen N: A peptidomimetic inhibitor of farnesyl:protein transferase blocks the anchorage-dependent and -independent growth of human tumor cell lines. Cancer Research 55:5302\u2013309, 1995","journal-title":"Cancer Research"},{"key":"4345_CR20","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1126\/science.278.5340.1036","volume":"278","author":"M Barinaga","year":"1997","unstructured":"Barinaga M: From bench top to bedside. Science 278:1036\u2013039, 1997","journal-title":"Science"},{"key":"4345_CR21","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1200\/JCO.2002.09.116","volume":"20","author":"M Crul","year":"2002","unstructured":"Crul M, de Klerk GJ, Swart M, van\u2019t Veer LJ, de Jong D, Boerrigter L, Palmer PA, Bol CJ, Tan H, de Gast GC, Beijnen JH, Schellens JHM: Phase I clinical and pharmacologic study of chronic oral administration of the farnesyl protein transferase inhibitor R115777 in advanced cancer. J Clin Onco 20:2726\u2013735, 2002","journal-title":"Journal of Clinical Oncology"},{"key":"4345_CR22","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumors. J Nat Cancer Inst 92:205\u201316, 2000","journal-title":"Journal of the National Cancer Institute"},{"key":"4345_CR23","first-page":"131","volume":"61","author":"DW End","year":"2001","unstructured":"End DW, Smets G, Todd AV, Applegate TL, Fuery CJ, Angibaud P, Venet M, Sanz G, Poignet H, Skrzat S, Devine A, Wouters W, Bowden C: Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res 61:131\u201337, 2001","journal-title":"Cancer Research"},{"key":"4345_CR24","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/bmb\/64.1.227","volume":"64","author":"JS de Bono","year":"2002","unstructured":"de Bono JS, Rokinsky EK: Therapeutics targeting signal transduction for patients with colorectal carcinoma. British Med Bull 64:227\u201354, 2002","journal-title":"British Medical Bulletin"},{"key":"4345_CR25","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1038\/nrc1234","volume":"3","author":"SM Sebti","year":"2003","unstructured":"Sebti SM, Der CJ: Searching for the elusive targets of farnesyltransferase inhibitors. Nat Rev Cancer 3:945\u201351, 2003","journal-title":"Nature Reviews Cancer"},{"key":"4345_CR26","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1200\/JCO.2003.08.040","volume":"21","author":"SJ Cohen","year":"2003","unstructured":"Cohen SJ, Ho L, Ranganathan S, Abbruzzese JL, Alpaugh RK, Beard M, Lewis NL, Mclaughlin S, Rogatko A, Perez-Ruixo JJ, Thistle AM, Verhaeghe T, Wang H, Weiner LM, Wright JJ, Hudes GR, Meropol NJ: Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Onco 21:1301\u2013306, 2003","journal-title":"Journal of Clinical Oncology"},{"key":"4345_CR27","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.1182\/blood.V97.11.3361","volume":"97","author":"JE Karp","year":"2001","unstructured":"Karp JE, Lancet JE, Kaufmann SH, End DW, Wright JJ, Bol K, Horak I, Tidwell ML, Liesveld J, Kottke TJ, Ange D, Buddharaju L, Gojo I, Highsmith WE, Belly RT, Hohl RJ, Rybak ME, Thibault A, Rosenblatt J: Clinical and biologic activity of the farnesyltransferase inhibitor R115777 in adults with refractory and relapsed acute leukemias: A phase 1 clinical-laboratory correlative trial. Blood 97:3361\u2013369, 2001","journal-title":"Blood"},{"key":"4345_CR28","doi-asserted-by":"publisher","first-page":"3950","DOI":"10.1200\/JCO.2004.10.037","volume":"22","author":"S Rao","year":"2004","unstructured":"Rao S, Cunningham D, de Gramont A, Scheithauer W, Smakal M, Humblet Y, Kourteva G, Iveson T, Andre T, Dostalova J, Illes A, Belly R, Perez-Ruxio JJ, Park YC, Palmer PA: Phase III double-blind placebo-controlled study of farnesyltransferase inhibitor R115777 in patients with refractory advanced colorectal cancer. J Clin Onco 22:3950\u2013957, 2004","journal-title":"Journal of Clinical Oncology"},{"key":"4345_CR29","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1200\/JCO.2003.09.075","volume":"21","author":"AA Adjei","year":"2003","unstructured":"Adjei AA, Mauer A, Bruzek L, Marks RS, Hillman S, Geyer S, Hanson LJ, Wright JJ, Erichman C, Kaufmann SH, Vokes EE: Phase II study of the farnesyl transferase inhibitor R115777 in patients with advanced non-small-cell lung cancer. J Clin Onco 21:1760\u2013766, 2003","journal-title":"Journal of Clinical Oncology"},{"key":"4345_CR30","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1200\/JCO.2004.10.112","volume":"22","author":"E Van Cutsem","year":"2004","unstructured":"Van Cutsem E, van de Velde H, Karasek P, Oettle H, Vervenne WL, Szawlowski A, Schoffski P, Post S, Verslype C, Neumann H, Safran H, Humblet Y, Perez Ruxio J, Ma Y, Von Hoff D: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Onco 22:1430\u2013438, 2004","journal-title":"Journal of Clinical Oncology"},{"key":"4345_CR31","unstructured":"Lancet JE: Farnesyltransferase inhibitors in acute myelogenous leukemia. Paper presented at 8th Annual International Congress on Hematological Malignancies: Focus on Leukemias, Lymphomas, and Myelomas; March 10\u201314, 2004; Whistler, British Columbia, Canada"},{"key":"4345_CR32","first-page":"8758","volume":"61","author":"RB Lobell","year":"2001","unstructured":"Lobell RB, Omer CA, Abrams MT, Bhimnathwala HG, Brucker MJ, Buser CA, Davide JP, deSolms SJ, Dinsmore CJ, Ellis-Hutchings MS, Kral AM, Liu D, Lumma WC, Machotka SV, Rands E, Williams TM, Graham SL, Hartman GD, Oliff AI, Heimbrook DC, Kohl NE: Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 61:8758\u2013768, 2001","journal-title":"Cancer Research"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-4345-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-005-4345-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-4345-3","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-005-4345-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T13:13:20Z","timestamp":1678540400000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-005-4345-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,1,28]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["4345"],"URL":"https:\/\/doi.org\/10.1007\/s10637-005-4345-3","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,1,28]]},"assertion":[{"value":"28 January 2006","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}